Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.

Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005

Open access
Holst, J. J. · 2006 · Diabetologia

Abstract

The incretin hormones are intestinal polypeptides that enhance postprandial insulin secretion. Gastric inhibitory polypeptide (GIP) was initially thought to regulate gastric acid secretion, whereas glucagon-like peptide-1 (GLP-1) was discovered as a result of a systematic search for intestinal insulinotropic products of proglucagon gene expression. The incretin effect is markedly impaired or absent in patients with type 2 diabetes because of decreased secretion of GLP-1 and a loss of the insulinotropic effects of GIP. Metabolic control can be restored or greatly improved by administration of exogenous GLP-1, but this peptide is almost immediately degraded by dipeptidyl peptidase IV (DPP-IV), and therefore has little clinical value. DPP-IV-resistant analogues (incretin mimetics) have been identified or developed, and inhibitors of DPP-IV have also proved effective in protecting endogenous GLP-1 (and GIP) from degradation. Both principles have been tested in clinical studies. The incretin mimetics, administered by sc injection, have demonstrated lasting improvement in HbA(1)c in patients insufficiently treated with conventional oral therapy, and their use has been associated with steady weight loss for up to 2 years. The DPP-IV inhibitors, given once or twice daily by mouth, also appear to provide lasting improvement in HbA(1)c, but are weight-neutral. The first incretin mimetic has reached the market in the US, and applications for approval of the first inhibitors are expected to be filed early in 2006.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-005-0107-1

Cites

95 of 95 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 95 references

Research works printed but not linked: 4

  1. Holst JJ, Orskov C, Schwartz TW, Buhl T, Baldissera F (1986) Proglucagon 78-107, a potent insulinotropic hormone from the lower small intestine. Diabetologia 29:549A (Abstract)
  2. Larsen J, Jallad J, Damsbo P (1996) One-week continuous infusion of GLP-1(7-37) improves glycemic control in NIDDM. Diabetes 45:233A (Abstract)
  3. Ehlers MRW, Roderick EH, Schneider RL, Kipnes MS (2002) Continuous subcutaneous infusion of recombinant GLP-1 for 7 days dose-dependently improved glycemic controls in type 2 diabetes. Diabetes 51:A579 (Abstract)
  4. Nauck M, Hompesch M, Filipczak R et al (2004) Liraglutide as add-on to metformin in type 2 diabetes: significant improvement in glycaemic control with a reduction in body weight compared with glimepiride. Diabetologia 47:A281 (Abstract)

Cited by

See all 253

Metadata

Authors
Holst, J. J.
Affiliations
University of Copenhagen (DK)
Corresponding author
Holst, J. J.
Venue
Diabetologia
Published
2006-01-14
Volume
49
Issue
2
Pages
253-260
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W2082032596
Cited by
228
References
95
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 9 · 2020: 5 · 2019: 6 · 2018: 6 · 2017: 5 · 2016: 10 · 2015: 13 · 2014: 7 · 2013: 13 · 2012: 16
FWCI
4.31
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Diabetologia (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
  • Sundhed og Sygdom, Det Frie Forskningsråd
  • European Foundation for the Study of Diabetes
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
glucagon-like peptide-1, incretins, glucose-dependent insulinotropic polypeptide, proglucagon, type 2 diabetes, insulin secretion, incretin mimetics, DPP-4 inhibitors, dipeptidyl peptidase IV, HbA1c, weight loss, oral antidiabetic drugs
MeSH terms
Glucagon-Like Peptide-1 Receptor, Exenatide, Insulin Secretion, Blood Glucose, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Intestines, Peptides, Protease Inhibitors, Venoms, Receptors, Glucagon, Dipeptidyl Peptidase 4, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. https://app.cochat.ai/papers/10.1007/s00125-005-0107-1
The paper
Holst, J. J. (2006). Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia. https://doi.org/10.1007/s00125-005-0107-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.